Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats
Journal of Veterinary Internal Medicine · 2023
DOI: 10.1111/jvim.16689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2023. Verfasst von Virginie Fabrès und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ecole Nationale Veterinaire d'Alfort, CHUVA, Service de médecine interne, Maisons-Alfort, Île-de-France, F-94700, France. Hauptthemen laut MEDLINE: Cat Diseases, Hyperaldosteronism, Hypertension. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Development of a telmisartan-based suppression test may facilitate the diagnosis of primary hyperaldosteronism (PHA) in cats, which remains difficult today.
Objectives
To develop a telmisartan suppression test (TST) that is safe, and able to suppress aldosterone secretion in healthy cats but not in cats with PHA. Animals Ten healthy cats and 6 cats with PHA.
Methods
Prospective study using a placebo-controlled crossover design to investigate a TST in healthy cats, and evaluation of TST in cats with PHA. Plasma aldosterone concentration, potassium concentration, and systolic blood pressure (SBP) were measured before (T0), and 1 hour (T1) and 1.5 hours after (T1.5) PO administration of 1 mg/kg of telmisartan, 2 mg/kg of telmisartan or placebo.
Results
Median age in healthy cats was 3 years old (range, 1-7). In healthy cats, a telmisartan dose of 2 mg/kg significantly decreased aldosterone concentration at T1 and T1.5 compared with T0. Placebo had no significant effect on aldosterone concentration. In cats diagnosed with PHA, a 2-mg/kg dose of telmisartan did not induce any significant change in aldosterone concentration at T1 or T1.5 compared with T0. No adverse effects of telmisartan (e.g., hyperkalemia, systemic hypotension) were observed in any cats. Conclusions and Clinical Importance The oral TST shows promise as a diagnostic test for the diagnosis of PHA in cats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ecole Nationale Veterinaire d'Alfort, CHUVA, Service de médecine interne, Maisons-Alfort, Île-de-France, F-94700, France.
- Centre Hospitalier Vétérinaire Aquivet, Service de médecine interne, F-33320, Eysines (Bordeaux), France.
- Centre Hospitalier Veterinaire Frégis, Service de médecine interne, 43 avenue Aristide Briand, Arcueil, 94110, France.
- Micen Vet, Service de médecine interne, Créteil, France.
- VetAgro Sup, Service de Pathologie clinique, Marcy-l'Etoile, Auvergne-Rhône-Alpes, France.
- AzurVet-Lab, Laboratoire de biologie médicale, St-Laurent-du-Var, France.
ORCID-Profile: Renaud Dumont, Maxine Kurtz, Ghita Benchekroun
Zitieren
APA
Fabrès, V., Dumont, R., Garcia, M., Rosenberg, D., Rannou, B., Kurtz, M., & Benchekroun, G. (2023). Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16689
Vancouver
Fabrès V, Dumont R, Garcia M, Rosenberg D, Rannou B, Kurtz M, et al. Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16689
BibTeX
@article{Fabrs2023,
author = {Fabrès, Virginie and Dumont, Renaud and Garcia, Mélanie and Rosenberg, Dan and Rannou, Benoit and Kurtz, Maxine and Benchekroun, Ghita},
title = {Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats},
journal = {Journal of Veterinary Internal Medicine},
year = {2023},
doi = {10.1111/jvim.16689}
}
EUVIMED